IL6R and rheumatoid arthritis: Tocilizumab, an inhibitory IL-6R antibody, that is approved for rheumatoid arthritis, juvenile idiopathic arthritis, Castleman's disease, and Crohn's disease [49–52], inhibits IL-6 signaling.